Recruiting
Phase 2
Phase 3

Inhaled Insulin vs. Injections

Sponsor:

Jaeb Center for Health Research

Code:

NCT06535789

Conditions

Diabetes, Gestational

Pregnancy Complications

Glucose Metabolism Disorders

Glucose Intolerance During Pregnancy

Eligibility Criteria

Sex: Female

Age: 18 - 40

Healthy Volunteers: Not accepted

Interventions

Inhaled Technosphere Insulin

Study Details

Brief summary:

Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.

Conditions

Diabetes, Gestational

Pregnancy Complications

Glucose Metabolism Disorders

Glucose Intolerance During Pregnancy

Study ID

NCT06535789

Start date

May, 2025

Status verified date

May, 2025

Completion date

Jul, 2025

Anticipated

Primary completion date

Jul, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 40

Healthy Volunteers: Not accepted

Inclusion Criteria

1. Ability to provide informed consent for study participation
2. Age ≥18 years and <41 years old
3. Singleton pregnancy at 24-34 weeks gestation
4. Diagnosis of GDM via standard 1-step or 2-step criteria
5. Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose <20 units
6. Pre-pregnancy or first trimester body mass index (BMI) 25-45
7. Investigator believes that the protocol can be safely conducted by the participant
8. Able to read and speak English

Exclusion Criteria

1. Type 1 diabetes or type 2 diabetes
2. HbA1c ≥ 6.5%, FBG ≥125 mg/dl or 2-hr glucose ≥200 mg/dL on 75g OGTT, or random plasma glucose ≥200 mg/dL (consistent with pre-existing diabetes and not GDM diagnosis)
3. Current use of any non-insulin glucose lowering medication
4. Using TI (Afrezza), regular insulin, or ≥20 RAA units at breakfast (NPH is permissible)
5. Peak expiratory flow <80% predicted as measured by peak flow meter
6. Recent history of asthma (defined as using any medications to treat asthma within the last year), chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator
7. Smoking (includes cigarettes, cigars, pipes, and/or vaping devices) within 90 days prior to screening
8. History or current diagnosis of lung cancer
9. Current or anticipated use of oral, inhaled or injectable glucocorticoids during the time period of the trial (topical glucocorticoid use is acceptable)
10. Renal or hepatic impairment that in the investigator's judgment poses a safety risk for the study participant
11. Recurrent Level 2 (blood glucose <54 mg/dL) or Level 3 severe hypoglycemia events
12. Current use of non-cardio-selective beta blockers
13. Being a member of the study team, having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: technosphere insulin (TI)

All participants will ingest one standardized meal using technosphere insulin to manage their blood glucose

no intervention: Rapid-acting insulin analog

All participants will ingest one standardized meal using their prescribed rapid-acting insulin analog (RAA) to manage their blood glucose

Interventions

Inhaled Technosphere Insulin

Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal

Primary outcome measure

  • Post-prandial AUC120 [ Time Frame: 3 hours from start of meal ]

Central Contacts and Locations

Central contacts

Katrina Ruedy, MSPH

813-975-8690kruedy@jaeb.org

Jennifer Gurley

jgurley@jaeb.org

Locations

Sansum Diabetes Research Institute

Recruiting

Santa Barbara, California, United States, 93105

Contacts

Principal Investigator:

Kristin Castorino, MD

University of Colorado Anschutz Medical Campus

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Principal Investigator:

Linda A Barbour, MD

Icahn School of Medicine at Mount Sinai

Recruiting

New York City, New York, United States, 10029

Contacts

Principal Investigator:

Carol Levy, MD

Oregon Health and Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Principal Investigator:

Amy Valent, DO

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Principal Investigator:

Celeste Durnwald, MD

More Information

Sponsor

Jaeb Center for Health Research

Last update posted

May 15, 2025

Last verified

May, 2025

Keywords

  • Gestational Diabetes
  • Inhaled Insulin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Jaeb Center for Health Research on 2025-05-15.